Myriad Genetics Announces Presentation of Prostate Cancer Study at American Society for Clinical Oncology Annual Meeting
Researchers analyzed the Company's 46-gene CCP panel, PROLARIS™, for 352 men whose clinically localized prostate cancer was diagnosed by needle biopsy. They compared the predictive nature of the CCP score in biopsies to the accepted clinical variables including Gleason score, baseline PSA, age, clinical stage and the extent of the disease. The study further analyzed PROLARIS™ as a predictor of cancer death for prostate cancer patients managed conservatively through observation and active surveillance.
Myriad believes the market need for the PROLARIS™ product stems from the limited ability of current markers to accurately predict prostate cancer aggressiveness at time of biopsy. Many men diagnosed with prostate cancer have indolent disease that can be safely monitored with active surveillance, whereas some patients have aggressive cancer and need immediate treatment. The challenge facing all men diagnosed with prostate cancer is to decide whether to have aggressive therapy, such as radiation or radical prostatectomy, which has potentially significant complications such as, incontinence and impotence or to monitor the disease through active surveillance. Overtreatment of prostate cancer and its attendant complications is widely recognized as an important public health issue and places an unnecessary financial burden on the health care system. The PROLARIS™ product, which incorporates the CCP score, was developed to meet this significant need to improve the physician's ability to predict disease outcome and to thereby optimize treatment.
Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the Company's anticipated presentation of a prostate cancer study at the
Rebecca ChambersDirector, Investor Relations and Corporate Communications (801) 584-1143 firstname.lastname@example.org
News Provided by Acquire Media